Late Relapse Is Rare in Testicular Cancer
Data suggest that 0.5% of patients with clinical stage I testicular cancer experience relapse after 10 years.
Testicular Cancer
Modifiable AHOs Are Prognostic in Testicular Cancer Survivors
Modifiable adverse health outcomes affect overall mortality and cancer mortality in testicular cancer survivors.
Study Reveals Causes of Premature Death in Testicular Cancer Survivors
Certain treatments were associated with an increased risk of death unrelated to testicular cancer.
Uniform Care of Testicular Cancer Overcame Sociodemographic Factors
Guideline-directed care resulted in equivalent outcomes independent of hospital setting.
Long-Term AEs Persist in Some Survivors of Testicular Cancer
A subset of testicular cancer survivors experience persistent, treatment-related, long-term adverse health outcomes that affect their ability to work.
One-Cycle BE500P Seems Safe for High-Risk Early Testicular Cancer
Malignant recurrence rate was 1.3 percent at two years for one-cycle BE500P in high-risk early-stage disease.
Testicular Cancer Treatment Regimens
Get the latest treatment regimens for testicular cancer, including options such as carboplatin, EP + cisplatin, BEP, and VIP.
Adjuvant BEP for 1 Cycle Safe, Efficacious for Testicular Cancer
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
TP53, MDM2 Alterations Linked to Cisplatin Resistance in Testicular Cancer
TP53 and MDM2 alterations are associated with resistance to cisplatin and inferior progression-free survival among patients with metastatic germ cell tumors.
Twins Study Suggests Strong Familial Risk for Testicular Cancer
A study of twins with 22 980 individuals suggested that the familial risk for testicular cancer may be dramatically underestimated.
- Loading...
Loading...
Next post in Male Reproductive Cancers
Loading... 
Loading...